Skip to main content
. 2016 Mar 8;24(5):855–866. doi: 10.1038/mt.2016.33

Figure 3.

Figure 3

AAV9-IGHMBP2 strengthens the hindlimb and forearms of nmd females and males. (a,b) Rotarod performance was used to measure riding time parameter in seconds; low- and high-dose-injected nmd females (a) and males (b) were compared with the times of their age-matched untreated nmd littermates (one-way ANOVA P < 0.0001) and “Het” (one-way analysis of variance (ANOVA), ns). (c,d) Grip strength measurements in grams; low- and high-dose-treated nmd females (c) and males (d) were compared with their age-matched untreated nmd and “Het” littermates (one-way ANOVA P < 0.0001). Measurements were taken from P63 through P69. Error bars represent ± SE. (e,f) Suspended from the tail, all untreated nmd mice show severe hindlimb contracture compared with age-matched “Het” control (photo taken at P56) (e), while all AAV9-IGHMBP2-treated nmd have rescued hindlimb contracture compared to untreated (photo taken at P50) (f).